Drug Survival of Biologics in Patients With Hidradenitis Suppurativa

Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease

(2020) Mayte Gil-Candel et al.   International Journal of Clinical Pharmacy

Unknown

(2019)   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis

(2018) A. Egeberg et al.   BRITISH JOURNAL OF DERMATOLOGY

Comparative Analysis and Predictors of 10-year Tumor Necrosis Factor Inhibitors Drug Survival in Patients with Spondyloarthritis: First-year Response Predicts Longterm Drug Persistence

(2018) Irini D. Flouri et al.   JOURNAL OF RHEUMATOLOGY

Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents

(2017) Łukasz Matusiak et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

The Follicular Skin Microbiome in Patients With Hidradenitis Suppurativa and Healthy Controls

(2017) Hans Christian Ring et al.   JAMA Dermatology

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

(2016) Alexa B. Kimball et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adherence to TNF-alpha inhibitors in patients with hidradenitis suppurativa

(2014) Simon Francis Thomsen et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Association of Metabolic Syndrome and Hidradenitis Suppurativa

(2014) Iben Marie Miller et al.   JAMA Dermatology

Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa

(2013) Alexa B. Kimball et al.   ANNALS OF INTERNAL MEDICINE

Hidradenitis Suppurativa

(2012) Gregor B.E. Jemec   NEW ENGLAND JOURNAL OF MEDICINE

Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β

(2011) H.H. van der Zee et al.   BRITISH JOURNAL OF DERMATOLOGY